Clinical Trials Sponsored by AGC Biologics S.p.A.

Total 39 results

AGC Biologics S.p.A.

Terminated

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia (TK008)

Acute Leukemia (Category)

Israel, United States, Germany, France, Spain, Belgium, Italy, Greece, Lithuania, Portugal
AGC Biologics S.p.A.

Completed

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

Hematological Malignancies

Italy, Israel, United Kingdom, Germany, Greece
AGC Biologics S.p.A.

Completed

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Colon Cancer

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

Cancer

Italy, Netherlands
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (NGR010)

Malignant Pleural Mesothelioma

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

Solid Tumors

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Solid Tumors

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Italy
AGC Biologics S.p.A.

Completed

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Advanced Solid Tumors

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (NGR007)

Small Cell Lung Cancer

Italy
AGC Biologics S.p.A.

Completed

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Malignant Pleural Mesothelioma

United States, Spain, United Kingdom, Ireland, Italy, Belgium, Egypt, Canada, France, Netherlands, Poland, Sweden
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

Colorectal Cancer (CRC)

Italy
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (NGR019)

Advanced Malignant Pleural Mesothelioma

Italy, Germany, Russian Federation
AGC Biologics S.p.A.

Completed

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Ovarian Cancer

Italy
AGC Biologics S.p.A.

Completed

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

Ovarian Cancer Metastatic Recurrent

Italy
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NGR018)

Ovarian Cancer

Italy, United Kingdom
AGC Biologics S.p.A.

Completed

NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Italy
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

Metastatic Adult Soft Tissue Sarcoma

France, Italy, United Kingdom
AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
Andres J. M. Ferreri
AGC Biologics S.p.A.

Completed

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor (INGRID)

Lymphoma, Large B-Cell, Diffuse

Italy
LimmaTech Biologics AG

Completed

Phase I to Test a New Pneumococcal Vaccine

Pneumonia, Bacterial | Pneumococcal Pneumonia

Germany
LimmaTech Biologics AG
GlaxoSmithKline

Recruiting

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Recurrent Vulvovaginal Candidiasis

Belgium
LimmaTech Biologics AG
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

Klebsiella Pneumoniae Infection

Germany
S.L.A. Pharma AG

Recruiting

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Familial Adenomatous Polyposis

Italy
S.L.A. Pharma AG

Completed

Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

FAP | Familial Adenomatous Polyposis Coli

United Kingdom
S.L.A. Pharma AG

Completed

Diltiazem Hydrochloride Cream for Anal Fissure

Chronic Anal Fissure

United Kingdom, Spain, Bulgaria, Germany, Lithuania, Romania
S.L.A. Pharma AG

Completed

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

Crohn's Disease

United Kingdom, United States
S.L.A. Pharma AG

Withdrawn

A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence

Faecal Incontinence

United Kingdom
S.L.A. Pharma AG

Completed

Naloxone SR Capsules in Patients With Opioid Induced Constipation

Chronic Pain | Opioid Induced Constipation

Germany, United Kingdom
S.L.A. Pharma AG

Completed

A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy

Haemorrhoidectomy

United Kingdom
S.L.A. Pharma AG

Recruiting

EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

SARS-CoV-2

Spain, United Kingdom
S.L.A. Pharma AG

Not yet recruiting

Metronidazole Ointment in Non-healing Pilonidal Sinus Wounds

Pilonidal Sinus

Turkey
S.L.A. Pharma AG

Completed

Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease

Perianal Crohns'

United Kingdom
S.L.A. Pharma AG

Completed

Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa

Adenomatous Polyps

Italy, United Kingdom
LimmaTech Biologics AG
Wellcome Trust; Naval Medical Research Center

Completed

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

Shigellosis

United States
LimmaTech Biologics AG
Johns Hopkins Bloomberg School of Public Health

Completed

Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a

Shigellosis

United States
LimmaTech Biologics AG
KEMRI-Wellcome Trust Collaborative Research Program; Kenya Medical Research...

Completed

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Shigellosis

Kenya
Grupo de Investigação em Bioquímica e Biologia...
Ivoclar Vivadent AG

Unknown

Comparison of the Efficacy and Quality of Life of Three Bleaching Products

Quality of Life | Tooth Bleaching

Portugal
Federal Research Clinical Center of Federal Medical...
Novagenesis Foundation; Ophiuchus Technologies AG

Unknown

Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury

Spinal Cord Injury

Russian Federation

3

Subscribe